血小板衍化内皮细胞生长因子在肝癌中的表达及干预治疗  

The expression of platelet-derived endothelial cell growth factor in liver cancer

作　　者：周俭[1] 汤钊猷[1] 樊嘉[1] 吴志全[1] 纪元[1] 鲍卫华 王鲁[1] 叶胜龙[1] 

机构地区：[1]上海医科大学肝癌研究所上海医科大学附属中山医院,200032

出　　处：《中华医学杂志》2000年第11期831-834,共4页National Medical Journal of China

基　　金：上海市百人计划基金! (97BR0 2 9) ;上海市科技发展基金! (9844190 6 7);美国中华医学基金! (93 5 83)资助项目

摘　　要：目的　了解血小板衍化内皮细胞生长因子 (PD ECGF)在肝癌中的表达 ,探讨与其相关的卡培他滨 (capecitabine ,CAP)治疗对肝癌生长和转移的作用。方法　用免疫组织化学法检测 6 1例肝细胞癌 (HCC)患者肝组织中PD ECGF蛋白水平。应用NorthernBlot法对其中 2 8例HCC组织中PD ECGFmRNA水平作相对定量分析。用 2 4只裸鼠人肝癌高转移模型LCI D2 0 ,于肿瘤种植后第 3天分别采用不同剂量CAP治疗。停药后第 3天处死裸鼠 ,测量肿瘤的长短径 ,并用HE染色检测肺转移。结果　 6 1例HCC和癌周组织中PD ECGF蛋白表达阳性率分别为 70 .5 %和 47.5 % ,37例高TNM分期组 (Ⅲ期和Ⅳ期 )HCC组织中PD ECGF蛋白表达阳性率 (81.1% )明显高于 2 4例低TNM分期组 (Ⅰ期和Ⅱ期 )表达率 (5 4.2 % ) ,两者差异有显著意义 (P <0 .0 5 )。NorthernBlot分析 ,HCC组织的PD ECGF蛋白水平表达与其相应mRNA水平变化一致。CAP 2 .10mmol·kg-1·day-1和 3.15mmol·kg-1·day-1治疗组裸鼠肝癌体积 (2 40mm3± 119mm3 和 2 0 9mm3± 15 0mm3)明显小于对照组 (4 47mm3± 15 9mm3) (P<0 .0 5 )。裸鼠肺转移率随CAP剂量的增加而下降 (P <0 .0 5 )。结论　PD ECGF在HCC组织中高表达 ,与肝癌TNM分期相关。CAP能抑制HCC的生长和转移。Objective To investigate the expression of platelet derived endothelial cell growth factor (PD ECGF) in liver cancer and explore its related intervention with Capecitabine for the growth and metastasis of liver cancer. Methods The protein level of PD ECGF was determined using immunohistochemical method in 61 HCC samples and the mRNA level was detected using Northern blot analysis. Capecitabine was administered orally in 24 nude mice bearing LCI D20 tumor. All treatments lasted 3 weeks. The tumor size was calculated by the following formula: V=a×b 2×0.5. Lung metastasis was evaluated by HE staining in lung samples. Results The PD ECGF expression rate in 61 HCC and paratumoral liver tissues was 70.5% and 47.5%, respectively. The rate was higher in HCC tissues with advanced TNM stage than in those with early TNM stage (81.1% vs 54.2%, P<0.05). The mRNA level of PD ECGF was related well to its protein expression. The tumor size on day 3 after last treatment measured in the control, and low dose (1.05 mmol·kg -1 ·day -1 ), moderate dose (2.10 mmol·kg -1 ·day -1 ) and high dose (3.15 mmol·kg -1 ·day -1 ) of Capecitabine treatment groups was 447 mm 3±159 mm 3, 414 mm 3±97 mm 3, 240 mm 3±119 mm 3 and 209 mm 3±150 mm 3, respectively. High doses of Capecitabine increased the inhibitory effect on the growth and lung metastasis of HCC implant. Conclusion PD ECGF is highly expressed in HCC and correlates with the TNM staging. Capecitabine may inhibit the growth and metastasis of HCC.

关 键 词：肝癌 血小板衍化内皮细胞生长因子 表达 治疗 

分 类 号：R735.7[医药卫生—肿瘤]